ReviewFrontiers in cell and developmental biology2025
Exploring the interconnectedness of multiple sclerosis and erectile dysfunction: mechanisms and management strategies.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erectile dysfunction (ED) is common in men with multiple sclerosis (MS) and arises from convergent neurogenic, autonomic, vascular, inflammatory, and psychosocial pathways. We synthesize epidemiologic prevalence and risk data on ED in MS, map mechanistic pathways linking central and spinal lesions, autonomic-endothelial imbalance, and psychosocial modulators to ED phenotypes, and provide a stage-based care algorithm integrating neuro-urological testing and psycho-sexological support. Across more than 30 studies, pooled ED prevalence in men with MS is approximately 50%, with higher odds at greater disability and with co-existing lower urinary tract symptom (LUTS) and depression. Phosphodiesterase-5 inhibitors (PDE5i) are commonly used as first-line pharmacologic therapy, although data specific to MS remain limited and individual response can vary. Device-, injection-, neuromodulation-, and prosthesis-based options offer escalation pathways. Evidence quality varies and residual confounding and detection bias remain possible.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.